Market: NASD |
Currency: USD
Address: 4300 El Camino Real
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
📈 Unicycive Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$55.67
-
Upside/Downside from Analyst Target:
1,203.67%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.100000 |
- |
2025-06-20 |
- |
Stock split |
|
Total Amount for 2025: $0.100000 |
📅 Earnings & EPS History for Unicycive Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2025-08-14 | -0.52 |
| 2025-05-14 | -0.5 |
| 2025-03-31 | -2.6 |
| 2024-11-13 | -0.5 |
| 2024-08-14 | 1.5 |
| 2024-05-13 | -6.1 |
| 2024-03-28 | -1.6 |
| 2023-11-14 | -1.3 |
| 2023-08-14 | -2.9 |
| 2023-05-16 | -9.7 |
| 2023-03-31 | -3.5 |
| 2022-11-14 | -3.7 |
| 2022-08-15 | -2.4 |
| 2022-05-12 | -2.4 |
| 2022-03-31 | -1.7 |
| 2021-11-12 | -3.7 |
| 2021-08-16 | -1.3 |
📰 Related News & Research
No related articles found for "unicycive therapeutics".
